iShares US Pharmaceuticals ETF
99 hedge funds and large institutions have $91M invested in iShares US Pharmaceuticals ETF in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 12 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 21
50% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 12
15% more capital invested
Capital invested by funds: $78.9M → $91M (+$12.1M)
8.28% more ownership
Funds ownership: 67.77% → 76.05% (+8.3%)
5% more funds holding
Funds holding: 94 → 99 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.93M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$1.93M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$1.24M |
| 4 |
LPL Financial
San Diego,
California
|
+$988K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$974K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.49M |
| 2 |
CFGS
Concourse Financial Group Securities
Birmingham,
Alabama
|
-$3.55M |
| 3 |
DS
DRW Securities
Chicago,
Illinois
|
-$568K |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$294K |
| 5 |
FWCM
Ferguson Wellman Capital Management
Portland,
Oregon
|
-$240K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
101
Candriam SCA
Strassen, Luxembourg,
Luxembourg
| – | -$294K | -5,400 | Closed |
|
|
FWCM
102
Ferguson Wellman Capital Management
Portland,
Oregon
| – | -$240K | -4,410 | Closed |
|
|
SG
103
StoneX Group
New York
| – | -$234K | -4,290 | Closed |
|
|
AA
104
Advisory Alpha
Holland,
Michigan
| – | -$61K | -1,089 | Closed |
|
|
AP
105
Advisors Preferred
Rockville,
Maryland
| – | -$45K | -819 | Closed |
|
|
AAMA
106
Advanced Asset Management Advisors
Dublin,
Ohio
| – | -$42K | -771 | Closed |
|
|
HGWM
107
Harvest Group Wealth Management
Waltham,
Massachusetts
| – | -$13.9K | -243 | Closed |
|
|
PFS
108
Prospera Financial Services
Dallas,
Texas
| – | -$13K | -240 | Closed |
|
109
Simplex Trading
Chicago,
Illinois
| – | -$3K | -72 | Closed |
|
|
CSPIA
110
Cary Street Partners Investment Advisory
Richmond,
Virginia
| – | -$3K | -51 | Closed |
|
IHE Hedge Fund Activity: Q4 2020 in Review
99 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2020, worth a combined $91M — up 15% from $78.9M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new IHE positions and 12 closed out — a net gain of 6 holders — while 33 added to existing stakes and 21 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $5.93M. The largest seller was Susquehanna International Group, cutting an estimated $6.49M.
- 99 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2020, up from 94 in Q3 2020.
- Funds reported $91M of iShares US Pharmaceuticals ETF stock for Q4 2020, up 15% quarter-over-quarter.
- 18 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2020 and 12 closed out, a net change of +6 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q4 2020 was Tower Research Capital (TRC), an estimated $5.93M added.
- The largest iShares US Pharmaceuticals ETF seller in Q4 2020 was Susquehanna International Group, an estimated $6.49M sold.
Based on aggregated 13F filings for Q4 2020.